Eplontersen · Wainua

RNA / oligonucleotide

Approvedregulatory verdict

Evidence outlook

Approved: Transthyretin Amyloidosis with Polyneuropathy

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Weak signal

Also in development:Transthyretin Amyloidosis with Cardiomyopathy · Phase 3 · investigational in the US

Also approved (1)
EU
  • Treatment of hereditary transthyretin-mediated amyloidosis (ATTRv) in adult patients with stage 1 or stage 2 polyneuropathy.
Product first approved 2025EMA
Featured evidence outside this drug's tracked markets:NCT04302064 · Healthy Participants · Phase 1 · completed · ungraded

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (5)
Transthyretin Amyloidosis with Cardiomyopathy
NCT05667493 · Ionis Pharmaceuticals, Inc.
2022-11-30 – 2029-08 · Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
What this study did
NCT06194825 · AstraZeneca
2023-12-01 – 2027-01-05 · Transthyretin Amyloid Cardiomyopathy
What this study did
Other / comorbidity
NCT05071300 · Ionis Pharmaceuticals, Inc.
2022-01-04 – 2029-08 · Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
What this study did
Phase 1/2 (1)
Phase 1 (2)
Other / comorbidity
NCT06527755 · AstraZeneca
2024-08-06 – 2024-11-15 · Transthyretin-mediated Amyloidosis
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2 (1)
Transthyretin Amyloidosis with Cardiomyopathy
NCT07608354 · AstraZeneca
2026-06-11 – 2029-02-06 · Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
What this study did

Competitive landscape

This mechanism is crowded: 8 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Transthyretin Amyloidosis with Cardiomyopathy: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Eplontersen (Wainua): this drugPhase 3RNA / oligonucleotideTransthyretin (TTR)Partial signal
NCT04136171: CARDIO-TTRansform primary composite: rate ratio 0.89 (95% CI 0.73 to 1.09), P=0.28; no significant reduction. missed
Acoramidis (Attruby)ApprovedSmall moleculeTransthyretin (TTR)not yet gradedNo reviewed efficacy summary in this indication
Vutrisiran (AMVUTTRA)ApprovedRNA / oligonucleotideTransthyretin (TTR)Reliable signal
NCT04153149: Composite of all-cause mortality and recurrent cardiovascular events: overall population HR 0.718 (95% CI 0.555 to 0.929), p=0.0118; vutrisiran monotherapy subgroup HR 0.672 (95% CI 0.487 to 0.929), p=0.0162
CliramitugPhase 3Monoclonal antibodyTransthyretin (TTR)not yet gradedNo reviewed efficacy summary in this indication
Coramitug
Phase 3(overall)
Monoclonal antibodyTransthyretin (TTR)
not yet graded(overall)
No reviewed efficacy summary in this indication
Nexiguran ZiclumeranPhase 3Gene therapy / editingTransthyretin (TTR)not yet gradedNo reviewed efficacy summary in this indication
NucresiranPhase 3RNA / oligonucleotideTransthyretin (TTR)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Wainua (Eplontersen) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2029 (2)
August 2029 (2)
Phase 3Hereditary Transthyretin-Mediated Amyloid PolyneuropathyActive not recruiting
Est. primary completion 2029-08 · NCT05071300 · CT.gov ↗
What to watch
Phase 3Transthyretin Amyloidosis with CardiomyopathyEnrolling by invitation
Est. primary completion 2029-08 · NCT05667493 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

July 2026Topline resultPhase 3 CARDIO-TTRansform missed its primary endpoint